Selinexor in relapsed/refractory multiple myeloma

Multiple myeloma (MM) represents an incurable hematologic malignancy. Despite significant advances over the past decade, with the advent of multiple new classes of anti-myeloma agents, including immunomodulatory drugs, proteasome inhibitors and monoclonal antibodies, patients ultimately relapse. Sel...

Full description

Saved in:
Bibliographic Details
Published in:Therapeutic Advances in Hematology 2020-01, Vol.11, p.2040620720930629-2040620720930629
Main Authors: Richter, Joshua, Madduri, Deepu, Richard, Shambavi, Chari, Ajai
Format: Article
Language:English
Subjects:
Advances in Multiple Myeloma (MM)
Blood cancer
Multiple myeloma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Multiple myeloma (MM) represents an incurable hematologic malignancy. Despite significant advances over the past decade, with the advent of multiple new classes of anti-myeloma agents, including immunomodulatory drugs, proteasome inhibitors and monoclonal antibodies, patients ultimately relapse. Selinexor is a first-in-class exportin-1 inhibitor with activity in these multiply relapsed and refractory patients. Although the current Food and Drug Administration (FDA) approval is for the doublet of Selinexor in combination with dexamethasone, ongoing clinical trials are evaluating a number of combination regimens. These triplet and quadruplet, selinexor-based, regimens are showing significant activity in “triple-class” refractory patients. With appropriate combination drug choice, drug dosing, and supportive measures, patients with previously no viable options for therapy, now have multiple potential regimens to control their disease.
ISSN:2040-6207
2040-6215
DOI:10.1177/2040620720930629